A new drug, still under investigation and not yet FDA approved is reported to provide the benefits of exercise in humans. The drug is called ATX304 and has been studied in humans in phase II clinical trials. It works by decreasing the degradation of a master energy controller called AMPK (AMP-activated protein kinase) By decreasing the degradation, it increases the amount of AMPK which has multiple favorable metabolic effects. When we exercise our muscles utilize ATP (adenosine triphosphate) the major energy source for our cells. When ATP is broken down the levels of AMP (adenosine monophosphate) increase and that increase signals AMPK to increase. ATX304 produces the same rise in AMPK experienced with exercise. The result is that muscle cells uptake glucose from the circulation without the need for insulin (non insulin dependent glucose uptake), the same occurs with exercise. With exercise the effect can last for 16 hours. Thus blood sugar is better controlled with both exercise and with ATX304. Along with better blood sugar control, insulin sensitivity is maintained and improved by avoiding pancreatic beta cell stress (beta cells produce insulin). ATX-304 also improves blood vessel flow, cardiac pump function, and as a result improved delivery of oxygen and nutrients to muscle and all parts of the body.
ATX304 also increases the uptake of fatty acids by the mitochondria (the organelle in our cells that produce energy in the form of ATP), facilitating energy production through the burning of fat (a process called beta oxidation). This happens without the muscle loss associated with GLP-1 drugs. Muscle is protected because glucose and fatty acid delivery to muscles are enhanced while keeping cellular ATP stable, completely bypassing the starvation pathways that cause muscle wasting when people lose weight by fasting or taking GLP-1 agonist drugs.
While I do not advocate taking pills instead of exercise I view ATX-304 as a better alternative weight loss medication compared to GLP-1 drugs for several reasons. First and foremost one can avoid the 20-40% loss of muscle associated with GLP-1 drugs. Secondly, ATX-304 increases metabolic rate, causing greater energy expenditure.
While ATX-304 represents an exciting potential approach to weight loss while improving insulin sensitivity without loss of muscle, you cannot build muscle strength, muscle mass, improve balance and coordination, or challenge your brain (with the resulting cognitive protection) by taking a pill. You must exercise including resistance training to accomplish those specific beneficial outcomes.
For a deeper dive into ATX-304 and a more detailed understanding how our bodies use glucose and fat to produce energy, as well as understanding how exercise works to improve metabolic health, what follows is a conversation I had with Google Gemini.
Conversation with Gemini
how does atx304 improve glucose control, enhance exercise performance and reduce body fat while maintaining muscle, use only peer reviewed scientific papers and cite references
ATX-304 (formerly known as O304) is a first-in-class, small-molecule, non-allosteric PAN-AMPK activator (AMP-activated protein kinase) currently in clinical development for metabolic and cardiovascular diseases (Ericsson et al., 2021; Steneberg et al., 2018). It functions primarily by protecting phosphorylated AMPK (p-AMPK) from dephosphorylation by protein phosphatases like PP2C, effectively acting as an “exercise mimetic” that triggers catabolic, energy-generating pathways (Steneberg et al., 2018).
Peer-reviewed academic research details the distinct physiological mechanisms through which ATX-304 improves glucose control, enhances exercise performance, and selectively targets body fat while preserving lean muscle mass:
1. Improvement of Glucose Control
ATX-304 manages blood sugar levels through a dual mechanism targeting both skeletal muscle and pancreatic tissues:
- Insulin-Independent Glucose Uptake: In skeletal muscle, ATX-304 activates AMPK signaling, which drives the translocation of glucose transporter 4 (GLUT4) vesicles to the cell membrane. This allows muscle tissue to pull glucose from the bloodstream independently of insulin action (Steneberg et al., 2018).
- Beta-Cell Preservation and Rest: By reducing systemic glucose demand and chronic hyperglycemia, the compound mitigates pancreatic β-cell stress. Clinical evidence from Phase IIa trials in patients with Type 2 Diabetes (T2D) demonstrated substantial reductions in fasting plasma glucose (FPG) and overall insulin resistance, quantified by HOMA-IR (Steneberg et al., 2018).
- Reversal of Age-Related Insulin Resistance: In longitudinal animal models, prolonged administration of the compound prevented the progressive, age-associated hyperinsulinemia that typically induces metabolic syndrome (Ericsson et al., 2021).
2. Enhancement of Exercise Performance
As an exercise mimetic, ATX-304 induces cellular adaptations similar to endurance training:
- Cardiovascular & Microvascular Remodeling: ATX-304 mimics the cardiac stressors of exercise by enhancing left ventricular stroke volume, increasing end-diastolic volume, and lowering resting heart rate without inducing pathological cardiac hypertrophy (Ericsson et al., 2021; Steneberg et al., 2018). Furthermore, it improves peripheral microvascular perfusion and blood pressure regulations.
- Mitochondrial Homeostasis: The compound enhances mitochondrial respiration, upregulates fatty acid oxidation, and increases baseline oxygen consumption rates (OCR) in metabolic tissues (Katerelos et al., 2024). These changes directly translate to significantly improved exercise capacity and total work endurance, especially in aged or metabolically compromised subjects (Ericsson et al., 2021).
3. Reduction of Body Fat While Maintaining Muscle
One of the key advantages of direct pan-AMPK activation via ATX-304 is its ability to execute a systemic “metabolic switch” that differentiates between fat tissue and lean body mass:
- Upregulation of Lipid Oxidation: ATX-304 stimulates cellular catabolism by phosphorylating Acetyl-CoA Carboxylase (ACC). Phosphorylation inhibits ACC, which decreases malonyl-CoA levels, disinhibits carnitine palmitoyltransferase-1 (CPT1), and permits rapid fatty acid oxidation in both the liver and adipose tissue (Holm et al., 2024).
- Selective Adiposity Loss: Body composition analysis via EchoMRI reveals that the rapid weight reduction induced by ATX-304 corresponds almost entirely to a loss in adipose (fat) mass (Holm et al., 2024). It also limits hepatic de novo lipogenesis and drives down blood cholesterol levels.
- Muscle Preservation (Lean Weight Maintenance): Unlike severe caloric restriction or certain anti-obesity medications that trigger concurrent muscle loss, animals treated with ATX-304 maintain their absolute lean weight (muscle mass) (Holm et al., 2024). The compound drives a significant long-term increase in energy expenditure, meaning that even when food intake naturally rebounds or increases by 20% to 30%, fat mass continues to decrease while skeletal muscle architecture is protected (Holm et al., 2024).
References
Ericsson, M., Steneberg, P., Nyrén, R., & Edlund, H. (2021). AMPK activator O304 improves metabolic and cardiac function, and exercise capacity in aged mice. Communications Biology, 4(1), 1–12. https://doi.org/10.1038/s42003-021-02837-0 Cited by: 30
Holm, E., Vermeulen, I., Parween, S., López-Pérez, A., Cillero-Pastor, B., Vandenbosch, M., Remeseiro, S., & Hörnblad, A. (2024). AMPK-activator ATX-304 reduces oxidative stress and improves MASLD via metabolic switching. JCI Insight, 9(7). https://doi.org/10.1101/2024.02.13.578901 Cited by: 10
Katerelos, M., Gleich, K., Harley, G., Loh, K., Oakhill, J. S., Kemp, B. E., de Souza, D. P., Narayana, V. K., Coughlan, M. T., Laskowski, A., Ling, N. X. Y., Murray-Segal, L., Brink, R., Lee, M., Power, D. A., & Mount, P. F. (2024). The AMPK activator ATX-304 alters cellular metabolism to protect against cisplatin-induced acute kidney injury. Biomedicine & Pharmacotherapy, 175, 116730. https://doi.org/10.1016/j.biopha.2024.116730 Cited by: 9
Steneberg, P., Lindahl, E., Dahl, U., Lidh, E., Straseviciene, J., Backlund, F., Kjellkvist, E., Berggren, E., Lundberg, I., Bergqvist, I., Ericsson, M., Eriksson, B., Linde, K., Westman, J., Edlund, T., & Edlund, H. (2018). PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients. JCI Insight, 3(12). https://doi.org/10.1172/jci.insight.99114 Cited by: 132
how do the effects on ACC and CPT1 lead to increased fat oxidation
The biochemical mechanism linking Acetyl-CoA Carboxylase (ACC) and Carnitine Palmitoyltransferase-1 (CPT1) is the primary pathway through which AMPK activators like ATX-304 accelerate fat oxidation.
In cellular metabolism, CPT1 is the “gatekeeper” for fat burning, but its activity is strictly regulated by a molecular brake called malonyl-CoA. Direct activation of AMPK breaks this cycle, shifting the cell into a dedicated fat-burning state.
The Molecular Chain Reaction
When ATX-304 activates AMPK, it initiates a sequential cascade that directly impacts the mitochondria:
ATX-304 / AMPK Activated
│
▼
ACC is Phosphorylated
(Inactivated)
│
▼
Malonyl-CoA Levels Drop
(The “Brake” is Removed)
│
▼
CPT1 is Disinhibited
(Gate Opens)
│
▼
Fatty Acids Enter Mitochondria ──► Beta-Oxidation (Fat Burning)
1. The Inactivation of ACC
Under normal conditions, the enzyme ACC converts acetyl-CoA into malonyl-CoA. Malonyl-CoA is the fundamental building block for synthesizing new fatty acids (de novo lipogenesis).
When ATX-304 activates AMPK, AMPK attaches a phosphate group to ACC (specifically the ACC1 and ACC2 isoforms). This phosphorylation inactivates ACC, halting the production of malonyl-CoA.
2. The Disinhibition of CPT1
Malonyl-CoA acts as a powerful allosteric inhibitor (a biological “off switch”) for CPT1. CPT1 is an enzyme anchored to the outer mitochondrial membrane. Long-chain fatty acids cannot cross into the mitochondria on their own; they must be attached to carnitine by CPT1 to gain entry.
Because ATX-304 shuts down ACC, cellular levels of malonyl-CoA rapidly drop. Without malonyl-CoA around to inhibit it, CPT1 transitions into its fully active state.
3. Increased Mitochondrial Beta-Oxidation
With the CPT1 gateway open, long-chain fatty acids are rapidly converted into acyl-carnitines, allowing them to pass through the mitochondrial membranes via the carnitine shuttle. Once inside the mitochondrial matrix, these fatty acids undergo β-oxidation (beta-oxidation).
During β-oxidation, the fatty acids are chopped down into acetyl-CoA molecules, which directly feed into the Tricarboxylic Acid (TCA) cycle to generate ATP (cellular energy).
Summary: By turning off ACC, ATX-304 depletes the molecule (malonyl-CoA) that normally blocks CPT1. This unlocks the mitochondrial gateway, forcing the cell to pull circulating fatty acids out of storage and burn them for fuel, ultimately driving down systemic body fat (Holm et al., 2024; Steneberg et al., 2018).
Want to know how this specific fat-burning pathway preserves muscle mass?
Yes
How does ATX-304 increase fat oxidation via ACC and CPT1 without triggering skeletal muscle breakdown or protein degradation?
The preservation of skeletal muscle mass during accelerated fat oxidation is a defining feature of ATX-304. Typically, extreme caloric restriction or non-selective metabolic stressors that force fat burning also trigger a counter-regulatory catabolic state, where muscle tissue is broken down for amino acids.
ATX-304 avoids skeletal muscle breakdown through several distinct molecular and metabolic safeguards:
1. Preservation of Cellular ATP Levels
diabetesjournals.org
Traditional methods of AMPK activation (like mitochondrial poisons or extreme energy deprivation) severely deplete cellular ATP. When ATP drops drastically, hyper-activated AMPK signals the cell that it is starving, which triggers the ubiquitin-proteasome system (via MuRF1 and MAFbx/Atrogin-1) and FoxO3-mediated autophagy to degrade muscle protein for emergency energy.
- The ATX-304 Difference: ATX-304 activates AMPK by preventing the dephosphorylation of p-AMPK by protein phosphatases, rather than by draining the cell of energy (Steneberg et al., 2018).
- Peer-reviewed data confirms that cellular ATP levels and mitochondrial membrane potential (MMP) are fully preserved under ATX-304 exposure (Diabetes, 2026). Because the muscle cell is never in a true energetic crisis or ATP deficit, the signals that initiate muscle proteolysis (protein degradation) are never switched on.
diabetesjournals.org
2. Enhanced Glucose and Nutrient Delivery to Muscle
insight.jci.org
Muscle wasting often occurs when a lack of localized energy forces muscle fibers to degrade. ATX-304 directly protects muscle tissue by optimizing its nutrient environment:
- GLUT4 Translocation: In skeletal muscle, ATX-304-driven AMPK activation stimulates the moving of GLUT4 transporters to the cell membrane, enhancing insulin-independent glucose uptake (Steneberg et al., 2018).
- Microvascular Perfusion: The compound improves capillary blood flow and microvascular perfusion directly to skeletal muscle tissue. This ensures a continuous supply of blood sugar, oxygen, and systemic nutrients to the muscle, keeping the tissue fueled and preventing the need for autophagic self-cannibalization.
3. Metabolic Substrate Switching Away from Proteolysis
By targeting the ACC-CPT1 axis, ATX-304 forces a highly selective “metabolic switch.”
- The inhibition of ACC stops fatty acid synthesis and drops malonyl-CoA levels, allowing CPT1 to constantly shuttle long-chain fatty acids into the mitochondria (Holm et al., 2024).
- This floods the mitochondrial matrix with lipids for β-oxidation. Because the cell is over-supplied with lipid-derived acetyl-CoA to feed the TCA cycle, it heavily relies on fat as its primary fuel source. Consequently, there is no biochemical demand to oxidize branched-chain amino acids (BCAAs) from structural muscle proteins.
4. Absence of the “Starvation Deficit” Loop
In long-term animal studies, subjects treated with ATX-304 experienced a substantial reduction in fat mass while maintaining absolute lean body weight (Holm et al., 2024). Because ATX-304 increases baseline energy expenditure through increased mitochondrial respiration, treated subjects naturally maintain a normal or slightly increased dietary intake to compensate. This stands in sharp contrast to crash dieting or GLP-1 receptor agonists, where profound appetite suppression and extreme caloric deficits frequently result in up to 20–40% of the lost weight coming from lean muscle mass.
In short: ATX-304 accelerates fat burning through the ACC-CPT1 pathway without sacrificing muscle because it increases lipid availability and muscle glucose uptake while keeping cellular ATP stable—completely bypassing the starvation pathways that cause muscle wasting.
References
- Holm, E., et al. (2024). AMPK-activator ATX-304 reduces oxidative stress and improves MASLD via metabolic switching. JCI Insight, 9(7).
- Steneberg, P., et al. (2018). PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients. JCI Insight, 3(12).
pmc.ncbi.nlm.nih.gov
- American Diabetes Association (ADA) Scientific Sessions. (2026). Abstract 1788-P: AMPK Activation by ATX-304 Is Not Secondary to Changes in ATP Levels. Diabetes, 75(Supplement 1).
diabetesjournals.org+ 1
THIS WEBSITE PROVIDES INFORMATION FOR EDUCATIONAL PURPOSES ONLY. CONSULT YOUR HEALTH CARE PROVIDER FOR MEDICAL ADVICE.
Eat clean, drink filtered water, love, laugh, exercise outdoors in a greenspace, get some morning sunlight, block the blue light before bed, engage in meaningful work, find a sense of purpose, spend time with those you love, AND sleep well tonight.
Doctor Bob
Practical Evolutionary Health 